"When 10-year-old Xiaohui asked 'how long will I live?', CAR-T technology made her the first person to rewrite the history of childhood leukemia treatment in China"
In the history of leukemia treatment, recurrence and drug resistance have been like deep chasms, plunging countless patients and doctors into predicaments. In the era of traditional chemotherapy, patient survival rates remained stubbornly low; for patients with relapsed and refractory acute myeloid leukemia (AML), the five-year survival rate was even less than 10%. However, with breakthroughs in medical research, we have entered a new era of combating cancer cells with "precision-guided weapons" — targeted drugs, immunotherapies, and gene regulation technologies are rewriting the battle plans in unprecedented ways.
The cunning of leukemia cells lies in their ability to disguise, escape, and mutate. But scientists are gradually decoding their survival codes:
The latest 2025 clinical trials confirm that the oral IDH1 inhibitor Olutasidenib, in combination with azacitidine, achieves a 31% complete remission rate in patients with relapsed/refractory IDH1-mutated AML, with an overall response rate of 51% and remission lasting nearly 15 months. More critically, patients who have not been exposed to this drug show an even higher response rate (37% CR/CRh), lighting a beacon of hope for patients with primary drug resistance.
• Breaking Ground in Pediatric Transformed AML: 10-year-old Xiaohui's B-cell leukemia transformed into acute myeloid leukemia (AML) after chemotherapy, rendering traditional treatments ineffective. The team led by Zhang Hui in Guangzhou innovatively adopted CLL1-targeted CAR-T therapy — seven days after infusion, cancer cells plummeted from 6.7% to 0.36%, achieving complete negativity within 28 days. This marked China's first successful CLL1-CAR-T case, opening a lifeline for transformed leukemia patients with no other treatment options.
• Autologous Treatment Miracle in T-Cell Leukemia: Lu Daopei Hospital cured two relapsed T-acute lymphoblastic leukemia patients using CD7 CAR-T. Among them, Xiaoqiu, who suffered a full relapse after transplantation, achieved negative bone marrow residuals 21 days after treatment; 14-year-old Tongtong reached complete remission just 14 days after CAR-T cell infusion when chemotherapy had failed. This breakthrough solved the "inability to distinguish friend from foe" dilemma in T-cell tumor treatment.
Scientific Perspective: CAR-T therapy has evolved from the single CD19 target to new targets like CLL1 and CD7. Its core breakthrough lies in "teaching immune cells to recognize disguises" — genetically engineering T cells to precisely lock onto unique antigens on cancer cells.
Beneath cold statistical data lie stories of lives racing against death:
"How long will I live?" — this desperate question escaped Xiaohui when her leukemia relapsed for the second time, and her family was crippled by medical debts.
• 2016: Abandoned transplantation due to poverty after initial chemotherapy
• 2017: Lymphoblastic leukemia transformed into AML during relapse chemotherapy
• 2023: Became China's first child to receive CLL1-CAR-T treatment
The treatment process resembled a precision military operation:
1. Isolation: Extracting blood to screen T cells
2. Modification: Genetically engineering to implant CLL1 recognition programs
3. Expansion: Cultivating a "legion" of billions of anti-cancer cells in vitro
4. Infusion: Achieving complete clearance of bone marrow cancer cells within 28 days
Once unable to afford transplantation, this impoverished family regained hope through innovative clinical trials. Today, Xiaohui has returned to school, and her case is included in China's CAR-T therapy textbooks.
"Sentenced to death, but I'm not ready to die" — Paul, diagnosed with AIDS in 1988, was struck by AML in 2018. In 2019, he underwent bone marrow transplantation with CCR5-Δ32 mutant genes, becoming the world's 5th "City of Hope patient" cured of both leukemia and AIDS five years later. This surgery achieved two missions:
• Donor stem cells reconstructed a healthy hematopoietic system
• Gene mutation blocked HIV's pathway into immune cells
At 68, he set the record for the longest cured period with HIV, proving that elderly patients can also achieve new life through precision transplantation.
• Xiaolong: After two relapses following AML transplantation, the Seventh Affiliated Hospital of Sun Yat-sen University used reduced-intensity rejection prevention + donor lymphocyte infusion to induce a controlled graft-versus-leukemia effect, achieving a miraculous remission after ICU rescue.
• Aunt Chen: A 55-year-old patient with relapsed acute lymphoblastic leukemia experienced chills and high fever just 5 hours after CAR-T treatment at Northern Jiangsu Hospital. The medical team precisely controlled complications, clearing cancer cells within 4 weeks.
Patient Insight: These cases reveal common traits — medical innovation + personalized regimens + doctor-patient trust. When Xiaohui's attending physician Zhang Hui said, "We will turn the impossible into possible," it was this belief that helped terminal patients cross the threshold between life and death.
The battle against relapsed/refractory leukemia knows no borders, and Chinese research teams are emerging as key players:
The VEN-PRS risk model, published in Leukemia in 2025, integrates extramedullary lesions, epigenetic drug exposure history, and 7 genetic mutations (e.g., TP53, IDH2) to predict treatment outcomes of venetoclax combined with hypomethylating agents for the first time. This model categorizes patients into three risk groups, with a 3.8-fold difference in survival between medium and high-risk groups.
• Targeted Radiotherapy Breaks Through Drug Resistance Barriers: Lintuzumab-Ac225 (anti-CD33 radionuclide antibody) combined with CLAG-M chemotherapy achieves a 50% remission rate in TP53-mutated patients, benefiting 86.7% of high-risk patients.
• Functional Cure No Longer a Dream: U.S. studies confirm that IDH1/NPM1 co-mutated AML patients receiving Olutasidenib monotherapy achieve sustained deep remission for over 7 years detected by single-cell sequencing, ushering in an era of "cure without continued medication."
Clinical Insight: The 7-year follow-up of the Dutch MURANO study shows that patients achieving minimal residual disease (MRD) negativity after venetoclax treatment have a progression-free survival of 52.5 months, 2.9 times that of non-negativity patients. MRD detection sensitivity has exceeded one cancer cell in a million.
Current research is advancing from "prolonging survival" to "eradicating disease":
A global trial (NCT06445959) of Olutasidenib + azacitidine + BCL-2 inhibitor venetoclax has launched, aiming to increase remission rates in refractory AML by 40% through synergistic blocking of metabolic regulation + epigenetic modification + apoptosis induction pathways.
Technical Bottleneck | Breakthrough Path | Clinical Progress |
Target escape | Dual-target CAR-T (e.g., CD19/CD22) | 85% CR rate in Beijing Bo'ai Hospital trial |
T-cell exhaustion | Gene editing to enhance T-cell activity | In U.S. CRISPR-CAR-T trials |
Solid tumor infiltration | Nanorobot-delivered CAR-T | Preclinical breakthrough at Sun Yat-sen University Cancer Center |
• Molecular Cure: Single-cell multi-omics MRD (scMRD) technology can track individual mutated stem cells
• Immune Reconstruction: Regulatory T-cell infusion reduces transplant rejection risk
• Gene Editing: CRISPR technology for repairing pathogenic mutations (e.g., PHF19 gene) enters animal experiments
From chemotherapy's "carpet bombing" to CAR-T's "cellular-level sniping," from Paul Edmond's dual cure to Xiaohui's CAR-T rebirth, humanity's journey against leukemia embodies the dual redemption of science and humanity. As Chinese teams join the global first echelon in fields like CLL1 targeting and the VEN-PRS model, we witness not just medical progress, but a solemn commitment to life —
The vision of "turning leukemia into a manageable chronic disease" is becoming reality, and every patient's story reminds us: those once deemed "terminal illnesses" will ultimately retreat in the face of human wisdom.
EN
CN